9:15 AM ET
8-K
Business Update
Edesa Biotech Business Update
Edesa Biotech announced that the FDA has cleared its Investigational New Drug (IND) application for a Phase 2 clinical study of EB06 in vitiligo. This clearance allows the company to expand patient recruitment into the United States, with topline data expected in the fourth quarter of 2027.